122 related articles for article (PubMed ID: 21500491)
41. Alfuzosin 10 mg once daily improves sexual function in men with lower urinary tract symptoms and concomitant sexual dysfunction.
van Moorselaar RJ; Hartung R; Emberton M; Harving N; Matzkin H; Elhilali M; Alcaraz A; Vallancien G;
BJU Int; 2005 Mar; 95(4):603-8. PubMed ID: 15705088
[TBL] [Abstract][Full Text] [Related]
42. Efficacy and safety of combined therapy with terazosin and tolteradine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study.
Yang Y; Zhao XF; Li HZ; Wang W; Zhang Y; Xiao H; Zhang X
Chin Med J (Engl); 2007 Mar; 120(5):370-4. PubMed ID: 17376305
[TBL] [Abstract][Full Text] [Related]
43. [Tadalafil in patients with benign prostatic hyperplasia during conservative combined therapy].
Volkov AA; Petrichko MI; Budnik NV; Dukhin AR
Urologiia; 2013; (2):56, 58-9. PubMed ID: 23789365
[TBL] [Abstract][Full Text] [Related]
44. The relationship among lower urinary tract symptoms, prostate specific antigen and erectile dysfunction in men with benign prostatic hyperplasia: results from the proscar long-term efficacy and safety study.
Paick SH; Meehan A; Lee M; Penson DF; Wessells H
J Urol; 2005 Mar; 173(3):903-7. PubMed ID: 15711315
[TBL] [Abstract][Full Text] [Related]
45. [Efficacy of an alpha-blocker, alfuzosin, on urinary disorders in men with prostatic adenoma. Intermediate results of a European multicenter study].
Jardin A
Ann Urol (Paris); 1988; 22(5):333-40. PubMed ID: 2462402
[TBL] [Abstract][Full Text] [Related]
46. Lower urinary tract symptoms and male sexual dysfunction in Asia: a survey of ageing men from five Asian countries.
Li MK; Garcia LA; Rosen R
BJU Int; 2005 Dec; 96(9):1339-54. PubMed ID: 16287456
[TBL] [Abstract][Full Text] [Related]
47. [Using doxasosine and finasteride combination in the treatment of prostate adenoma].
Bogdanov AB; Luk'ianov IV; Veliev EI
Urologiia; 2006; (5):59-63. PubMed ID: 17444154
[TBL] [Abstract][Full Text] [Related]
48. [Clinical study of bunazosin hydrochloride, an alpha 1-adrenergic blocker, in benign prostatic obstruction and neurogenic bladder dysfunction].
Takita T; Kondo A; Mitsuya H; Otani T
Hinyokika Kiyo; 1987 Sep; 33(9):1375-84. PubMed ID: 2449057
[TBL] [Abstract][Full Text] [Related]
49. Ejaculatory disorders caused by alpha-1 blockers for patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: comparison of naftopidil and tamsulosin in a randomized multicenter study.
Masumori N; Tsukamoto T; Iwasawa A; Furuya R; Sonoda T; Mori M;
Urol Int; 2009; 83(1):49-54. PubMed ID: 19641359
[TBL] [Abstract][Full Text] [Related]
50. Risk factors for lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a community based population of healthy aging men: the Krimpen Study.
Kok ET; Schouten BW; Bohnen AM; Groeneveld FP; Thomas S; Bosch JL
J Urol; 2009 Feb; 181(2):710-6. PubMed ID: 19091352
[TBL] [Abstract][Full Text] [Related]
51. Association between erectile dysfunction and lower urinary tract symptoms due to benign prostatic hyperplasia in Nigerian men.
Ikuerowo SO; Akindiji YO; Akinoso OA; Akinlusi FM; Esho JO
Urol Int; 2008; 80(3):296-9. PubMed ID: 18480635
[TBL] [Abstract][Full Text] [Related]
52. [Doxazosin in the gastrointestinal therapeutic system (GITS) and doxazosin standard in patients with benign prostatic hyperplasia. Double-blind trial of efficacy and tolerability].
Gratzke P; Kirby RS
Fortschr Med Orig; 2000 Jul; 118 Suppl 2():83-92. PubMed ID: 15700491
[TBL] [Abstract][Full Text] [Related]
53. Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: sexual function.
Lowe FC
BJU Int; 2005 Jun; 95 Suppl 4():12-8. PubMed ID: 15871731
[TBL] [Abstract][Full Text] [Related]
54. Editorial comment.
de la Rosette JJ
Urology; 2010 Jun; 75(6):1458. PubMed ID: 20513508
[No Abstract] [Full Text] [Related]
55. Assessment of sexual dysfunction in patients with benign prostatic hyperplasia.
Rosen RC
BJU Int; 2006 Apr; 97 Suppl 2():29-33; discussion 44-5. PubMed ID: 16507051
[TBL] [Abstract][Full Text] [Related]
56. Efficacy and safety of tamsulosin hydrochloride compared to doxazosin in the treatment of Indonesian patients with lower urinary tract symptoms due to benign prostatic hyperplasia.
Rahardjo D; Soebadi DM; Sugandi S; Birowo P; Djati W; Wahyudi I
Int J Urol; 2006 Nov; 13(11):1405-9. PubMed ID: 17083392
[TBL] [Abstract][Full Text] [Related]
57. Treatment of lower urinary tract symptoms in benign prostatic hyperplasia and its impact on sexual function.
Miner M; Rosenberg MT; Perelman MA
Clin Ther; 2006 Jan; 28(1):13-25. PubMed ID: 16490576
[TBL] [Abstract][Full Text] [Related]
58. Ejaculatory dysfunction in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
Rosen RC; Fitzpatrick JM;
BJU Int; 2009 Oct; 104(7):974-83. PubMed ID: 19426189
[TBL] [Abstract][Full Text] [Related]
59. Alpha-adrenergic receptor antagonists in older patients with benign prostatic hyperplasia: issues and potential complications.
Fine SR; Ginsberg P
J Am Osteopath Assoc; 2008 Jul; 108(7):333-7. PubMed ID: 18648026
[TBL] [Abstract][Full Text] [Related]
60. [The effectiveness of naftopidil in patients with benign prostatic hyperplasia evaluated by QOL index].
Nakatsu H; Naoi M; Sekiyama K; Hamano S; Suzuki N; Tanaka M; Murakami S
Hinyokika Kiyo; 2007 Jan; 53(1):13-8. PubMed ID: 17310763
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
